86 related articles for article (PubMed ID: 4836134)
1. Factor VIII international units and reference materials.
Bangham DR; Brozović M
Thromb Diath Haemorrh; 1974 Mar; 31(1):3-11. PubMed ID: 4836134
[No Abstract] [Full Text] [Related]
2. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
Yee TT; Lee CA
Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
[No Abstract] [Full Text] [Related]
3. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
Mäkipernaa A; von Bonsdorff L
Haemophilia; 2008 May; 14(3):612-4. PubMed ID: 18312362
[No Abstract] [Full Text] [Related]
4. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
Kessler CM; Ludlam CA
Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
[No Abstract] [Full Text] [Related]
5. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
Toolis F; McKay G; Prowse CV
Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
[TBL] [Abstract][Full Text] [Related]
6. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
Lange D; Lazerson J
Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
[No Abstract] [Full Text] [Related]
7. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
Seremetis SV
Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
[No Abstract] [Full Text] [Related]
8. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
Hubbard AR; Rigsby P; Barrowcliffe TW
Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey.
Hay CR; Lozier JN; Lee CA; Laffan M; Tradati F; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A; Teitel J; Mannucci PM; Kasper CK
Thromb Haemost; 1996 Jan; 75(1):25-9. PubMed ID: 8713775
[TBL] [Abstract][Full Text] [Related]
10. [Preparation and use of factor VIII concentrates in hemophilia].
Vilar JM; Ortega F; Martin-Arias DM; Vazquez J; Navarro JL
Sangre (Barc); 1969; 14(1):57-64. PubMed ID: 5792112
[No Abstract] [Full Text] [Related]
11. Changes in CD4 count relative to product usage: findings from the transfusion safety study.
Hilgartner MW
Semin Hematol; 1993 Oct; 30(4 Suppl 5):7-9. PubMed ID: 7903481
[No Abstract] [Full Text] [Related]
12. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates.
Barrowcliffe TW
Thromb Haemost; 1993 Nov; 70(5):876-7. PubMed ID: 8128450
[No Abstract] [Full Text] [Related]
13. An international collaborative assay of factor VIII clotting activity.
Barrowcliffe TW; Kirkwood TB
Thromb Haemost; 1978 Oct; 40(2):260-71. PubMed ID: 734631
[No Abstract] [Full Text] [Related]
14. Factor VIII inhibitor and severity of hemophilia.
Schoppmann A; Waytes AT
Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
[No Abstract] [Full Text] [Related]
15. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
Gaerisch F; Stein P
Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
[TBL] [Abstract][Full Text] [Related]
16. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
17. Abnormal serum transaminase levels in patients with hemophilia A.
Cederbaum AI; Blatt PM; Levine PH
Arch Intern Med; 1982 Mar; 142(3):481-4. PubMed ID: 6802093
[TBL] [Abstract][Full Text] [Related]
18. High purity factor VIII and immune state in HIV.
Nurs Stand; 1993 Oct 6-12; 8(3):17. PubMed ID: 8217692
[No Abstract] [Full Text] [Related]
19. [Inhibitors suppression in hemophilia A with continued treatment of factor VIII].
Aznar JA; Jiménez C; García I; Martín G; Borrego D; Peiro A; Marty ML
Sangre (Barc); 1982; 27(4A):572. PubMed ID: 6818701
[No Abstract] [Full Text] [Related]
20. Report of the Subcommittee on Human Factor 8 (AHF) Preparations.
Wagner RH
Thromb Diath Haemorrh Suppl; 1967; 26():371-5. PubMed ID: 6064867
[No Abstract] [Full Text] [Related]
[Next] [New Search]
